Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: Compound-specific and area-specific distribution within the brain

European Neuropsychopharmacology

Volumn 19, Issue 8, 2009, Pages 533-541

  Barna, I ^a   Till, I ^a   Haller, J ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Brain; Concentration; Levels; Mice; SR 141716A; WIN 55,212

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; RIMONABANT;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG TISSUE LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; ANIMALS; BENZOXAZINES; BRAIN; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; LIGANDS; MALE; MICE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; TISSUE DISTRIBUTION;

EID: 67549144921     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.02.001     Document Type: Article

References (50)

1. Ashton J.C., and Milligan E.D. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr. Opin. Investig. Drugs 9 (2008) 65-75
2. Bederman I.R., and Previs S.F. Hormonal regulation of intracellular lipolysis in C57BL/6J mice: effect of diet-induced adiposity and data normalization. Metabolism 57 (2008) 1405-1413
3. Benamar K., Geller E.B., and Adler M.W. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain. J. Pharmacol. Exp. Ther. 325 (2008) 641-645
4. Collins D.R., Pertwee R.G., and Davies S.N. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br. J. Pharmacol. 115 (1995) 869-870
5. Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front. Horm. Res. 36 (2008) 135-145
6. Degn M., Lambertsen K.L., Petersen G., Meldgaard M., Artmann A., Clausen B.H., Hansen S.H., Finsen B., Hansen H.S., and Lund T.M. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J. Neurochem. 103 (2007) 1907-1916
7. Deshpande L.S., Sombati S., Blair R.E., Carter D.S., Martin B.R., and DeLorenzo R.J. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci. Lett. 411 (2007) 11-16
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
9. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., and Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75 (2000) 2434-2444
10. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 (2005) 352-358
11. Ferraro L., Tomasini M.C., Gessa G.L., Bebe B.W., Tanganelli S., and Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb. Cortex. 11 (2001) 728-733
12. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., and Uhl G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 1071 (2006) 10-23
13. Gunji H., Little R.A., and Hiraiwa K. Interleukin-6 deficiency increases blood volume without altering body composition in young mice. Cytokine 20 (2002) 30-37
14. Heffner T.G., Hartman J.A., and Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 13 (1980) 453-456
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
16. Hossain M., Chetana M., and Devi P.U. Late effect of prenatal irradiation on the hippocampal histology and brain weight in adult mice. Int. J. Dev. Neurosci. 23 (2005) 307-313
17. Kodas E., Cohen C., Louis C., and Griebel G. Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology 194 (2007) 161-171
18. Le Foll B., Forget B., Aubin H.J., and Goldberg S.R. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict. Biol. 13 (2008) 239-252
19. Leweke F.M., and Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 13 (2008) 264-275
20. Livy D.J., Schalomon P.M., Roy M., Zacharias M.C., Pimenta J., Lent R., and Wahlsten D. Increased axon number in the anterior commissure of mice lacking a corpus callosum. Exp. Neurol. 146 (1997) 491-501
21. Maccarrone M., Fiori A., Bari M., Granata F., Gasperi V., De Stefano M.E., Finazzi-Agro A., and Strom R. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb. Haemost. 95 (2006) 117-127
22. Martin B.R., and Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol. Dis. 5 (1998) 447-461
23. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
24. McCulloch M., Zhou X., Xu Y., Brunell S., and Spear L. Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 863 (2008) 258-265
25. McPartland J.M., Glass M., and Pertwee R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol. 152 (2007) 583-593
26. Mechoulam R., and Shohami E. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 36 (2007) 68-74
27. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., and Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
28. Molina-Holgado E., Guaza C., Borrell J., and Molina-Holgado F. Effects of cannabinoids on the immune system and central nervous system: therapeutic implications. BioDrugs 12 (1999) 317-326
29. Moreira F.A., and Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict. Biol. 13 (2008) 196-212
30. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
31. Nemeth B., Ledent C., Freund T.F., and Hajos N. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 54 (2008) 51-57
32. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., Perchuk A., Mora Z., Tagliaferro P.A., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Chirwa S.S., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D., Teasenfitz L., Arinami T., and Uhl G.R. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N. Y. Acad. Sci. 1139 (2008) 434-449
33. Palmer S.L., Thakur G.A., and Makriyannis A. Cannabinergic ligands. Chem. Phys. Lipids 121 (2002) 3-19
34. Panikashvili D., Shein N.A., Mechoulam R., Trembovler V., Kohen R., Alexandrovich A., and Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22 (2006) 257-264
35. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318 (2006) 304-311
36. Paton G.S., Pertwee R.G., and Davies S.N. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. Neuropharmacology 37 (1998) 1123-1130
37. Peters T.J.R. All About Albumin: Biochemistry, Genetics, and Medical Applications (1996), Academic Press Limited, London
38. Pinto J.C., Potie F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G.H., Cantrell C.H., and Howlett A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46 (1994) 516-522
39. Pozzi O., Misiano P., Clark G.D., and Visentin L. Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. Pharmacology 69 (2003) 158-163
40. Riedel G., and Davies S.N. Cannabinoid function in learning, memory and plasticity. Handb. Exp. Pharmacol. 168 (2005) 445-477
41. Rinaldi-Carmona M., Pialot F., Congy C., Redon E., Barth F., Bachy A., Brelière J.C., Soubrié P., and Le Fur G. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 58 (1996) 1239-1247
42. Rubin C.T., Capilla E., Luu Y.K., Busa B., Crawford H., Nolan D.J., Mittal V., Rosen C.J., Pessin J.E., and Judex S. Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 17879-1784
43. Rubio M., McHugh D., Fernandez-Ruiz J., Bradshaw H., and Walker J.M. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci. Lett. 421 (2007) 270-274
44. Shen M., and Thayer S.A. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783 (1998) 77-84
45. Shimizu T., and Yokotani K. Bidirectional roles of the brain 2-arachidonoyl-sn-glycerol in the centrally administered vasopressin-induced adrenomedullary outflow in rats. Eur. J. Pharmacol. 582 (2008) 62-69
46. Sluiter W., Oomens L.W., Brand A., and Van Furth R. Determination of blood volume in the mouse with 51chromium-labelled erythrocytes. J. Immunol. Methods 73 (1984) 221-225
47. Tiburu E.K., Bass C.E., Struppe J.O., Lorigan G.A., Avraham S., and Avraham H.K. Structural divergence among cannabinoids influences membrane dynamics: a 2H solid-state NMR analysis. Biochim. Biophys. Acta 1768 (2007) 2049-2059
48. Valenti M., Vigano D., Casico M.G., Rubino T., Steardo L., Parolaro D., and Di Marzo V. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol. Life Sci. 61 (2004) 945-950
49. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
50. Wade M.R., Degroot A., and Nomikos G.G. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur. J. Pharmacol. 551 (2006) 162-167